Company name
OGD2 Pharma
Company profile
OGD2 Pharma, a Remora Biotech venture, is a French biotechnology company developing proprietary, next generation biotherapies targeting O-acetylated GD2 (OAcGD2), a tumour-restricted variant of the commercially validated GD2 target.
OGD201, our lead asset, is a humanised IgG monoclonal antibody for the treatment of neuroblastoma, which is advancing through IND-enabling development with planned readiness for Phase I clinical in 2027.
Category
Emerging biotech company
Title of the presentation
OGD2 Pharma: Elevating the Standard of Care in Neuroblastoma
Speaker information
| Name | Position | Institution |
|---|---|---|
| Marco Alessandrini | COO | OGD2 Pharma |
